1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis Broad Agency Announcement invites proposals for innovative research leveraging biological properties and processes to advance national security.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Open to proposals from any eligible entity, including universities. Confirm the full requirements in the official notice before applying.
DARPA BIO TECHNOLOGIES toolkit (BAA HR001126S0003) is funded by Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office (BTO). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
On June 3, 2026, four DARPA Biological Technologies Office SBIR topics close simultaneously — SWiFT, BARK, EXPOSITION, and Medical Swarm Robotics. Combined Phase I plus Phase II potential exceeds $6 million per company, and together they sketch a coherent strategy of distributed, autonomous, dual-species combat casualty care that depends on small businesses, not primes, to actually build.
Read articleDARPA pre-released Release 6 of its FY26 SBIR BAA on September 2, 2026. Five of the seven SBIR topics belong to the Biological Technologies Office, and four of those describe one continuous problem: keeping a casualty alive with no surgeon, no imaging, and no evacuation. Here are the award sizes, the Direct-to-Phase-II gates, and the sequencing DARPA is buying.
Read articleDARPA BTO pre-released four FY26 SBIR/STTR topics on April 30, 2026, with proposals due June 3. Two topics — SWiFT and EXPOSITION — offer Direct-to-Phase-II awards up to $1.5M, bypassing the standard Phase I gate. Here is what each topic is actually solving, why the DP2 structure matters, and how small biotech, surgical robotics, and battlefield-medicine teams should decide whether to compete.
Read article